Paclitaxel / Casp3 Cancer Research Results

PacT, Paclitaxel: Click to Expand ⟱
Features:
Paclitaxel (brand name Taxol) is a chemotherapy medication used to treat ovarian cancer, esophageal cancer, breast cancer, lung cancer, Kaposi's sarcoma, cervical cancer, and pancreatic cancer. Administered by intravenous injection.
Derived from a natural product, Taxol (from Pacific Yew Tree).
Paclitaxel is a drug (chemotherapy; a taxane). Its dominant anticancer mechanism is microtubule stabilization, which disrupts normal mitosis and drives mitotic arrest/stress signaling that can culminate in apoptosis.


Paclitaxel – Cancer Pathway Matrix

Rank Pathway / Axis Cancer / Tumor Context Normal Tissue Context TSF Primary Effect Notes / Interpretation
1 Microtubule stabilization → Mitotic arrest Mitotic progression ↓; spindle dynamics impaired; cell division blocked Proliferating normal cells affected R, G Core cytotoxic mechanism Binds β-tubulin and stabilizes microtubules, preventing normal depolymerization required for mitosis.
2 Spindle assembly checkpoint activation Prolonged mitotic arrest → mitotic catastrophe or apoptosis Checkpoint stress in dividing tissues R, G Mitotic stress execution Cell fate depends on whether arrest resolves via apoptosis or mitotic slippage.
3 Intrinsic apoptosis (mitochondrial pathway) Caspase activation ↑; BAX/mitochondrial signaling engaged (context) Limited unless stressed G Cell death execution Often downstream of prolonged mitotic stress and mitochondrial perturbation.
4 ROS generation (secondary) ROS ↑ (context-dependent); oxidative stress amplification Oxidative stress possible in sensitive tissues R, G Stress amplifier ROS rise appears secondary to mitotic and mitochondrial dysfunction; may enhance apoptosis.
5 Nrf2 antioxidant response (adaptive) Nrf2 ↑ in some tumors; antioxidant buffering ↑; resistance potential Protective antioxidant signaling G Adaptive resistance axis Not a direct paclitaxel target; elevated Nrf2 may reduce drug sensitivity.
6 Drug resistance mechanisms P-glycoprotein (MDR1) ↑; β-tubulin alterations; survival rewiring — G Treatment failure driver Efflux pumps and tubulin adaptations are major clinical resistance mechanisms.
7 Myelosuppression — Neutropenia risk ↑ G Dose-limiting toxicity Bone marrow suppression is a primary clinical constraint.
8 Peripheral neuropathy — Sensory neuropathy risk ↑ G Dose-limiting toxicity Likely related to microtubule disruption in axonal transport.

Time-Scale Flag (TSF):
P = 0–30 min (drug binding begins)
R = 30 min–3 hr (mitotic stress signaling, ROS changes)
G = >3 hr (apoptosis, resistance adaptation, tissue toxicities)



Casp3, CPP32, Cysteinyl aspartate specific proteinase-3: Click to Expand ⟱
Source:
Type:
Also known as CP32.
Cysteinyl aspartate specific proteinase-3 (Caspase-3) is a common key protein in the apoptosis and pyroptosis pathways, and when activated, the expression level of tumor suppressor gene Gasdermin E (GSDME) determines the mechanism of tumor cell death.
As a key protein of apoptosis, caspase-3 can also cleave GSDME and induce pyroptosis. Loss of caspase activity is an important cause of tumor progression.
Many anticancer strategies rely on the promotion of apoptosis in cancer cells as a means to shrink tumors. Crucial for apoptotic function are executioner caspases, most notably caspase-3, that proteolyze a variety of proteins, inducing cell death. Paradoxically, overexpression of procaspase-3 (PC-3), the low-activity zymogen precursor to caspase-3, has been reported in a variety of cancer types. Until recently, this counterintuitive overexpression of a pro-apoptotic protein in cancer has been puzzling. Recent studies suggest subapoptotic caspase-3 activity may promote oncogenic transformation, a possible explanation for the enigmatic overexpression of PC-3. Herein, the overexpression of PC-3 in cancer and its mechanistic basis is reviewed; collectively, the data suggest the potential for exploitation of PC-3 overexpression with PC-3 activators as a targeted anticancer strategy.
Caspase 3 is the main effector caspase and has a key role in apoptosis. In many types of cancer, including breast, lung, and colon cancer, caspase-3 expression is reduced or absent.
On the other hand, some studies have shown that high levels of caspase-3 expression can be associated with a better prognosis in certain types of cancer, such as breast cancer. This suggests that caspase-3 may play a role in the elimination of cancer cells, and that therapies aimed at activating caspase-3 may be effective in treating certain types of cancer.
Procaspase-3 is a apoptotic marker protein.
Prognostic significance:
• High Cas3 expression: Associated with good prognosis and increased sensitivity to chemotherapy in breast, gastric, lung, and pancreatic cancers.
• Low Cas3 expression: Linked to poor prognosis and increased risk of recurrence in colorectal, hepatocellular carcinoma, ovarian, and prostate cancers.
Scientific Papers found: Click to Expand⟱
1325- EMD,  PacT,    Emodin enhances antitumor effect of paclitaxel on human non-small-cell lung cancer cells in vitro and in vivo
- vitro+vivo, Lung, A549
TumCP↓, Apoptosis↑, BAX↑, Casp3↑, Bcl-2↓, p‑Akt↓, p‑ERK↓, ChemoSideEff∅, ChemoSen↑,
1300- GA,  PacT,  carbop,    Gallic acid potentiates the apoptotic effect of paclitaxel and carboplatin via overexpression of Bax and P53 on the MCF-7 human breast cancer cell line
- in-vitro, BC, MCF-7
TumCCA↑, Apoptosis↑, P53↑, BAX↑, Casp3↑, Bcl-2↓,
805- GAR,  Cisplatin,  PacT,    Garcinol Exhibits Anti-Neoplastic Effects by Targeting Diverse Oncogenic Factors in Tumor Cells
- Review, NA, NA
ERK↓, PI3K/Akt↓, Wnt/(β-catenin)↓, STAT3↓, NF-kB↓, ChemoSen↑, COX2↓, Casp3↑, Casp9↑, BAX↑, Bcl-2↓, VEGF↓, TGF-β↓, HATs↓, E-cadherin↑, Vim↓, Zeb1↓, ZEB2↓, Let-7↑, MMP9↓, TumCCA↑, ROS↑, MMP↓, IL6↓, NOTCH1↓,
86- QC,  PacT,    Quercetin regulates insulin like growth factor signaling and induces intrinsic and extrinsic pathway mediated apoptosis in androgen independent prostate cancer cells (PC-3)
- vitro+vivo, Pca, PC3
BAD↑, IGFBP3↑, Cyt‑c↑, cl‑Casp9↑, Casp10↑, cl‑PARP↑, Casp3↑, IGF-1R↓, PI3K↓, p‑Akt↓, cycD1/CCND1↓, IGF-1↓, IGF-2↓, IGF-1R↓, MMP↓, Apoptosis↑, NA?,

Showing Research Papers: 1 to 4 of 4

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 4

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned ⓘ

NA?, 1,  

Redox & Oxidative Stress ⓘ

ROS↑, 1,  

Mitochondria & Bioenergetics ⓘ

MMP↓, 2,  

Core Metabolism/Glycolysis ⓘ

PI3K/Akt↓, 1,  

Cell Death ⓘ

p‑Akt↓, 2,   Apoptosis↑, 3,   BAD↑, 1,   BAX↑, 3,   Bcl-2↓, 3,   Casp10↑, 1,   Casp3↑, 4,   Casp9↑, 1,   cl‑Casp9↑, 1,   Cyt‑c↑, 1,  

Transcription & Epigenetics ⓘ

HATs↓, 1,  

DNA Damage & Repair ⓘ

P53↑, 1,   cl‑PARP↑, 1,  

Cell Cycle & Senescence ⓘ

cycD1/CCND1↓, 1,   TumCCA↑, 2,  

Proliferation, Differentiation & Cell State ⓘ

ERK↓, 1,   p‑ERK↓, 1,   IGF-1↓, 1,   IGF-1R↓, 2,   IGF-2↓, 1,   IGFBP3↑, 1,   Let-7↑, 1,   NOTCH1↓, 1,   PI3K↓, 1,   STAT3↓, 1,   Wnt/(β-catenin)↓, 1,  

Migration ⓘ

E-cadherin↑, 1,   MMP9↓, 1,   TGF-β↓, 1,   TumCP↓, 1,   Vim↓, 1,   Zeb1↓, 1,   ZEB2↓, 1,  

Angiogenesis & Vasculature ⓘ

VEGF↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 1,   IL6↓, 1,   NF-kB↓, 1,  

Drug Metabolism & Resistance ⓘ

ChemoSen↑, 2,  

Clinical Biomarkers ⓘ

IL6↓, 1,  

Functional Outcomes ⓘ

ChemoSideEff∅, 1,  
Total Targets: 44

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: Casp3, CPP32, Cysteinyl aspartate specific proteinase-3
4 Paclitaxel
1 Emodin
1 Gallic acid
1 carboplatin
1 Garcinol
1 Cisplatin
1 Quercetin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:182  Target#:42  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page